Exelixis Announces Webcasts of Investor Conference Presentations in June 2019

̶ Presentations to be webcast on www.exelixis.com

ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced that the company will be
presenting at the following three investor conferences in June 2019:

  • William Blair 39th Annual Growth Stock Conference: Exelixis
    is scheduled to present at 5:00 PM EDT / 2:00 PM PDT on Wednesday,
    June 5, 2019 in Chicago.
  • Goldman Sachs 40th Annual Global Healthcare Conference:
    Exelixis is scheduled to present at 11:40 AM EDT / 8:40 AM PDT on
    Wednesday, June 12, 2019 in Rancho Palos Verdes, CA.
  • BMO Capital Markets Prescription for Success Healthcare Conference:
    Exelixis is scheduled to present at 8:00 AM EDT / 5:00 AM PDT on
    Tuesday, June 25, 2019 in New York.

To access the webcast links, log onto www.exelixis.com and
proceed to the News & Events / Event Calendar page under the Investors &
Media heading. Please connect to the company’s website at least 15
minutes prior to each presentation to ensure adequate time for any
software download that may be required to listen to the webcasts.
Replays will also be available at the same location for 14 days
following each presentation.

About Exelixis

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in model
genetic systems, we established a broad drug discovery and development
platform that has served as the foundation for our continued efforts to
bring new cancer therapies to patients in need. Our discovery efforts
have resulted in four commercially available products, CABOMETYX® (cabozantinib),
COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib)
and MINNEBRO® (esaxerenone), and we have entered into
partnerships with leading pharmaceutical companies to bring these
important medicines to patients worldwide. Supported by revenues from
our marketed products and collaborations, we are committed to prudently
reinvesting in our business to maximize the potential of our pipeline.
We are supplementing our existing therapeutic assets with targeted
business development activities and internal drug discovery — all to
deliver the next generation of Exelixis medicines and help patients
recover stronger and live longer. Exelixis is a member of the Standard &
Poor’s (S&P) MidCap 400 index, which measures the performance of
profitable mid-sized companies. For more information about Exelixis,
please visit www.exelixis.com,
follow @ExelixisInc on
Twitter or like Exelixis,
 on Facebook.

Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are
registered U.S. trademarks. MINNEBRO is a registered Japanese trademark.


Investors Contact:
Susan Hubbard
EVP, Public
Affairs and

Investor Relations
Exelixis, Inc.
[email protected]

Media Contact:
Hal Mackins
For Exelixis, Inc.
[email protected]

Read the full article

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.